Evidence map›Paper›PMID 29692212›Full record

Observational studyTherapeutic advances in respiratory disease

Use of glucocorticoids in patients with COPD exacerbations in China: a retrospective observational study.

Jing Zhang, Jinping Zheng, Kewu Huang, Yahong Chen, Jingping Yang, Wanzhen Yao

Open access · goldAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Glucocorticoid Use in Patients Hospitalized with Chronic Obstructive Pulmonary Disease Exacerbations.International journal of chronic obstructive pulmonary disease · 2024
    Article
  6. Risk of Death and Cardiovascular Events Following an Exacerbation of COPD: The EXACOS-CV US Study.International journal of chronic obstructive pulmonary disease · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Jing ZhangDepartment of Respiratory Medicine, Peking University Third Hospital, Beijing, China.
Jinping ZhengState Key Laboratory of Respiratory Disease, National Clinical Research Center, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Kewu HuangDepartment of Pulmonary and Critical Care Medicine and Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Yahong ChenDepartment of Respiratory Medicine, Peking University Third Hospital, Beijing, China.
Jingping YangDepartment of Respiratory and Critical Care Medicine, Baogang Hospital, Third Affiliated Hospital of Inner Mongolia Medical College, Third School of Clinical Medicine, Inner Mongolia Regional Medical Center, Baotou, China.
Wanzhen YaoDepartment of Respiratory Medicine, Peking University Third Hospital, Beijing 100191, China.
Peking University · CNBeijing Chao-Yang Hospital · CNFirst Affiliated Hospital of Guangzhou Medical University · CNPeking University Third Hospital · CNThird Affiliated Hospital of Inner Mongolia Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute exacerbations of chronic obstructive pulmonary disease (AECOPD) are common in patients with underlying moderate to severe COPD and are associated with increased health and economic burden. International and Chinese guidelines recommend using glucocorticoids for the management of AECOPD because glucocorticoid therapy has been shown to benefit clinical outcomes. However, only scant data are available for current status of glucocorticoid therapy in hospitalized AECOPD patients in China. The aim of the study was to identify current use of glucocorticoids for the treatment of AECOPD in China.

methodsThis retrospective, multicenter, noninterventional study evaluated the treatment pattern of AECOPD in patients hospitalized from January 2014 to September 2014 at 43 sites (41 tertiary hospitals and two secondary hospitals) in China. The endpoints of the study were the percentage of patients receiving glucocorticoids by different routes of administration, doses and duration, mortality, and the mean length of hospitalization.

resultsA total of 4569 patients (90.17%) received glucocorticoids for AECOPD treatment. A combination of nebulized and systemic route was most frequently used (40.51%), followed by using nebulized route alone (38.00%), systemic route alone (15.45%), and inhaled route other than nebulization (6.04%). Furthermore, the most commonly prescribed glucocorticoids of the nebulized, intravenous, inhaled (other than nebulized) and oral route was budesonide (69.4%), methylprednisolone sodium succinate (45.31%), fluticasone propionate (19.54%), and prednisone acetate (11.90%), respectively. The in-hospital mortality rate was 1.24% and the mean length of hospitalization was 12.22 ± 6.20 days (± SD).

conclusionsOur study was the first study of the treatment pattern of glucocorticoids in the management of hospitalized AECOPD patients in China. Data indicates that there is a gap in the implementation of international guidelines for the treatment of AECOPD in China. Further studies are warranted to clarify the appropriate glucocorticoids strategy for the management of AECOPD to determine the optimal route of administration, dose and duration, and resulting clinical outcomes.

Indexed as

Administration, InhalationAdministration, IntravenousAgedAged, 80 and overChinaDisease ProgressionFemaleGlucocorticoidsHospital MortalityHumansLength of StayLungMaleMiddle AgedPatient AdmissionPulmonary Disease, Chronic ObstructiveGlucocorticoidsCOPDexacerbationglucocorticoidsnebulization

Identifiers

PMID29692212
PMCPMC5961923
OpenAlexW2801512047

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.